TCR² Therapeutics Announces Pipeline Priorities for 2023

January 5, 2023

https://www.globenewswire.com/news-release/2023/01/05/2583769/0/en/TCR-Therapeutics-Announces-Pipeline-Priorities-for-2023.html

CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq:TCRR), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced its pipeline priorities for 2023 as it concentrates resources on completing the ovarian cancer cohort in the Phase 2 clinical trial of gavo-cel and accelerating the development of its second-generation enhanced TRuC T-cell therapy programs, TC-510 and TC-520.

Read more at globenewswire.com

Related news for (TCRR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.